ELENBECESTAT

/static/temp/default.svg

Search structure


Synonyms	E-2609 E2609 Elenbecestat
Status
Molecule Category	UNKNOWN
UNII	RXJ96XL94H


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	AACUJFVOHGRMTR-DPXNYUHVSA-N
Smiles	C[C@H]1OC[C@]2(c3cc(NC(=O)c4cnc(C(F)F)cn4)ccc3F)N=C(N)SC[C@H]12
InChI	InChI=1S/C19H18F3N5O2S/c1-9-12-7-30-18(23)27-19(12,8-29-9)11-4-10(2-3-13(11)20)26-17(28)15-6-24-14(5-25-15)16(21)22/h2-6,9,12,16H,7-8H2,1H3,(H2,23,27)(H,26,28)/t9-,12-,19-/m1/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C19H18F3N5O2S
Molecular Weight	437.45
AlogP	3.1
Hydrogen Bond Acceptor	7.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	4.0
Polar Surface Area	102.49
Molecular species	NEUTRAL
Aromatic Rings	2.0
Heavy Atoms	30.0

Bioactivity

Mechanism of Action	Action	Reference
Beta-secretase 1 inhibitor	INHIBITOR	PubMed


Protein: Beta-secretase 1 Description: Beta-secretase 1 Organism : Homo sapiens P56817 ENSG00000186318

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Enzyme Protease Aspartic protease Aspartic protease AA clan Aspartic protease A1A subfamily	-	7	-	-	-

Assay Description	Organism	Bioactivity	Reference
In vivo inhibition of gamma-secretase in human assessed as reduction in CSF amyloid beta level at 400 mg, po administered as multiple dose for 14 days relative to control	Homo sapiens	85.0 %
In vivo inhibition of BACE1 in po dosed Beagle dog assessed as plasma level causing 50% reduction in amyloidbeta42 level in CSF administered as single dose measured after 4 to 49 hrs	Canis lupus familiaris	22.0 nM
In vivo inhibition of BACE1 in human assessed as reduction in amyloidbeta level at 75 mg administered once daily relative to control	Homo sapiens	80.0 %
In vivo inhibition of BACE1 in po dosed Beagle dog assessed as unbound plasma level causing 50% reduction in amyloidbeta42 level in CSF administered as single dose measured after 4 to 49 hrs	Canis lupus familiaris	8.1 nM
In vivo inhibition of BACE1 in human assessed as reduction in amyloidbeta40 level in CSF at 25 mg relative to control	Homo sapiens	56.0 %
In vivo inhibition of BACE1 in human assessed as reduction in amyloidbeta40 level in CSF at 50 mg relative to control	Homo sapiens	71.0 %
In vivo inhibition of BACE1 in human assessed as reduction in amyloidbeta40 level in CSF at 100 mg relative to control	Homo sapiens	83.0 %
In vivo inhibition of BACE1 in human assessed as reduction in amyloidbeta40 level in CSF at 200 mg relative to control	Homo sapiens	90.0 %
Inhibition of BACE1 (unknown origin) by cell-based assay	Homo sapiens	7.0 nM

Related Entries

Cross References

Resources	Reference
ChEMBL	CHEMBL4204869
DrugBank	DB15391
FDA SRS	RXJ96XL94H
Guide to Pharmacology	9818
PubChem	57827330
SureChEMBL	SCHEMBL2620149

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).